Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8642554rdf:typepubmed:Citationlld:pubmed
pubmed-article:8642554lifeskim:mentionsumls-concept:C0002062lld:lifeskim
pubmed-article:8642554lifeskim:mentionsumls-concept:C0026549lld:lifeskim
pubmed-article:8642554lifeskim:mentionsumls-concept:C0034801lld:lifeskim
pubmed-article:8642554lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8642554lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:8642554lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:8642554lifeskim:mentionsumls-concept:C0456387lld:lifeskim
pubmed-article:8642554lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:8642554lifeskim:mentionsumls-concept:C0678594lld:lifeskim
pubmed-article:8642554lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:8642554lifeskim:mentionsumls-concept:C0332514lld:lifeskim
pubmed-article:8642554pubmed:issue10lld:pubmed
pubmed-article:8642554pubmed:dateCreated1996-7-18lld:pubmed
pubmed-article:8642554pubmed:abstractTextSeveral 8-amino-5,9-methanobenzocyclooctenes have been prepared by asymmetric organic synthesis techniques. Opioid receptor affinity studies have revealed the virtual absence of enantioselectivity for receptor binding, particularly at the mu-receptor, for the (+)-3a-f and the (-)-3a-f series. It is noteworthy that inversion of configuration at the nitrogen-bearing carbon atom [5S,8S,9S)-8-amino-3-hydroxy-5, 9-methano-9-(methoxymethyl)-5-methylbenzocyclooctene, (+)-3a vs (5S,8S,9R)-8-amino-3-hydroxy-5, 9-methano-9-(methoxymethyl)-5-methylbenzocyclooctene, (dl)-22] resulted in a > 10-fold increase in kappa-receptor affinity. Antinociceptive studies demonstrated that (dl)-22 was a full kappa-agonist while (+)-3a and (-)-3a did not possess kappa-activity. Although both (dl)-22 and (+)-3a/(-)-3a had high affinity for the mu-receptor, these compounds did not act as high-affinity agonists or antagonists at this receptor.lld:pubmed
pubmed-article:8642554pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8642554pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8642554pubmed:languageenglld:pubmed
pubmed-article:8642554pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8642554pubmed:citationSubsetIMlld:pubmed
pubmed-article:8642554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8642554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8642554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8642554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8642554pubmed:statusMEDLINElld:pubmed
pubmed-article:8642554pubmed:monthMaylld:pubmed
pubmed-article:8642554pubmed:issn0022-2623lld:pubmed
pubmed-article:8642554pubmed:authorpubmed-author:GlickS DSDlld:pubmed
pubmed-article:8642554pubmed:authorpubmed-author:SebastianAAlld:pubmed
pubmed-article:8642554pubmed:authorpubmed-author:WandBBlld:pubmed
pubmed-article:8642554pubmed:authorpubmed-author:BidlackJ MJMlld:pubmed
pubmed-article:8642554pubmed:authorpubmed-author:DeecherD CDClld:pubmed
pubmed-article:8642554pubmed:authorpubmed-author:SchultzA GAGlld:pubmed
pubmed-article:8642554pubmed:authorpubmed-author:AlvaCClld:pubmed
pubmed-article:8642554pubmed:issnTypePrintlld:pubmed
pubmed-article:8642554pubmed:day10lld:pubmed
pubmed-article:8642554pubmed:volume39lld:pubmed
pubmed-article:8642554pubmed:ownerNLMlld:pubmed
pubmed-article:8642554pubmed:authorsCompleteYlld:pubmed
pubmed-article:8642554pubmed:pagination1956-66lld:pubmed
pubmed-article:8642554pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:8642554pubmed:meshHeadingpubmed-meshheading:8642554-...lld:pubmed
pubmed-article:8642554pubmed:meshHeadingpubmed-meshheading:8642554-...lld:pubmed
pubmed-article:8642554pubmed:meshHeadingpubmed-meshheading:8642554-...lld:pubmed
pubmed-article:8642554pubmed:meshHeadingpubmed-meshheading:8642554-...lld:pubmed
pubmed-article:8642554pubmed:meshHeadingpubmed-meshheading:8642554-...lld:pubmed
pubmed-article:8642554pubmed:meshHeadingpubmed-meshheading:8642554-...lld:pubmed
pubmed-article:8642554pubmed:meshHeadingpubmed-meshheading:8642554-...lld:pubmed
pubmed-article:8642554pubmed:meshHeadingpubmed-meshheading:8642554-...lld:pubmed
pubmed-article:8642554pubmed:meshHeadingpubmed-meshheading:8642554-...lld:pubmed
pubmed-article:8642554pubmed:meshHeadingpubmed-meshheading:8642554-...lld:pubmed
pubmed-article:8642554pubmed:meshHeadingpubmed-meshheading:8642554-...lld:pubmed
pubmed-article:8642554pubmed:year1996lld:pubmed
pubmed-article:8642554pubmed:articleTitleAsymmetric syntheses, opioid receptor affinities, and antinociceptive effects of 8-amino-5,9-methanobenzocyclooctenes, a new class of structural analogues of the morphine alkaloids.lld:pubmed
pubmed-article:8642554pubmed:affiliationDepartment of Chemistry, Rensselaer Polytechnic Institute, Troy, New York 12180-3590, USA.lld:pubmed
pubmed-article:8642554pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8642554pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8642554pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:8642554lld:chembl